Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

R. Gold, EW. Radue, G. Giovannoni, K. Selmaj, EK. Havrdova, X. Montalban, D. Stefoski, T. Sprenger, RR. Robinson, S. Fam, J. Smith, S. Chalkias, G. Giannattasio, G. Lima, W. Castro-Borrero

. 2020 ; 267 (10) : 2851-2864. [pub] 20200525

Language English Country Germany

Document type Clinical Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc21020065
E-resources Online Full text

NLK ProQuest Central from 1997-04-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-04-01 to 1 year ago

Links

PubMed 32451615
DOI 10.1007/s00415-020-09835-y
Knihovny.cz E-resources

OBJECTIVE: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED. METHODS: Eligible participants who completed 1-2 years of daclizumab beta treatment in SELECT/SELECTION received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years in SELECTED. Safety assessments were evaluated for the SELECTED treatment period; efficacy data were evaluated from first dose of daclizumab beta in SELECT/SELECTION. RESULTS: Ninety percent (410/455) of participants who completed treatment in SELECTION enrolled in SELECTED. Within SELECTED, 69% of participants received daclizumab beta for > 3 years, 39% for > 4 years, and 9% for > 5 years; 87% of participants experienced an adverse event and 26% a serious adverse event (excluding multiple sclerosis relapse). No deaths occurred. Overall, hepatic events were reported in 25% of participants; serious hepatic events in 2%. There were no confirmed cases of immune-mediated encephalitis. Based on weeks from the first daclizumab beta dose in SELECT/SELECTION, adjusted annualized relapse rate (95% confidence interval) for weeks 0-24 was 0.21 (0.16-0.29) and remained low on continued treatment. Overall incidence of 24-week confirmed disability progression was 17.4%. Mean numbers of new/newly enlarging T2 hyperintense lesions remained low; percentage change in whole brain volume decreased over time. CONCLUSIONS: The effects of daclizumab beta on clinical and radiologic outcomes were sustained for up to ~ 8 years of treatment. No new safety concerns were identified in SELECTED. TRIAL REGISTRATION: Clinicaltrials.gov NCT01051349; first registered on January 15, 2010.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020065
003      
CZ-PrNML
005      
20210830101656.0
007      
ta
008      
210728s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00415-020-09835-y $2 doi
035    __
$a (PubMed)32451615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Gold, Ralf $u St. Josef-Hospital/Ruhr-University Bochum, 44791, Bochum, Germany. ralf.gold@rub.de
245    10
$a Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study / $c R. Gold, EW. Radue, G. Giovannoni, K. Selmaj, EK. Havrdova, X. Montalban, D. Stefoski, T. Sprenger, RR. Robinson, S. Fam, J. Smith, S. Chalkias, G. Giannattasio, G. Lima, W. Castro-Borrero
520    9_
$a OBJECTIVE: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED. METHODS: Eligible participants who completed 1-2 years of daclizumab beta treatment in SELECT/SELECTION received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years in SELECTED. Safety assessments were evaluated for the SELECTED treatment period; efficacy data were evaluated from first dose of daclizumab beta in SELECT/SELECTION. RESULTS: Ninety percent (410/455) of participants who completed treatment in SELECTION enrolled in SELECTED. Within SELECTED, 69% of participants received daclizumab beta for > 3 years, 39% for > 4 years, and 9% for > 5 years; 87% of participants experienced an adverse event and 26% a serious adverse event (excluding multiple sclerosis relapse). No deaths occurred. Overall, hepatic events were reported in 25% of participants; serious hepatic events in 2%. There were no confirmed cases of immune-mediated encephalitis. Based on weeks from the first daclizumab beta dose in SELECT/SELECTION, adjusted annualized relapse rate (95% confidence interval) for weeks 0-24 was 0.21 (0.16-0.29) and remained low on continued treatment. Overall incidence of 24-week confirmed disability progression was 17.4%. Mean numbers of new/newly enlarging T2 hyperintense lesions remained low; percentage change in whole brain volume decreased over time. CONCLUSIONS: The effects of daclizumab beta on clinical and radiologic outcomes were sustained for up to ~ 8 years of treatment. No new safety concerns were identified in SELECTED. TRIAL REGISTRATION: Clinicaltrials.gov NCT01051349; first registered on January 15, 2010.
650    _2
$a dospělí $7 D000328
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    12
$a daklizumab $x škodlivé účinky $x terapeutické užití $7 D000077561
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin G $7 D007074
650    12
$a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    12
$a roztroušená skleróza $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Radue, Ernst-Wilhelm $u Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland
700    1_
$a Giovannoni, Gavin $u Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
700    1_
$a Selmaj, Krzysztof $u Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Montalban, Xavier $u Hospital Vall d'Hebron University, Barcelona, Spain
700    1_
$a Stefoski, Dusan $u Rush University Medical Center, Chicago, IL, USA
700    1_
$a Sprenger, Till $u DKD Helios Klinik Wiesbaden, Wiesbaden, Germany
700    1_
$a Robinson, Randy R $u AbbVie Inc., Redwood City, CA, USA
700    1_
$a Fam, Sami $u Biogen, Cambridge, MA, USA
700    1_
$a Smith, Jonathan $u Biogen, Maidenhead, UK
700    1_
$a Chalkias, Spyros $u Biogen, Cambridge, MA, USA
700    1_
$a Giannattasio, Giorgio $u Biogen, Cambridge, MA, USA
700    1_
$a Lima, Gabriel $u Biogen, Cambridge, MA, USA
700    1_
$a Castro-Borrero, Wanda $u Biogen, Cambridge, MA, USA
773    0_
$w MED00002835 $t Journal of neurology $x 1432-1459 $g Roč. 267, č. 10 (2020), s. 2851-2864
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32451615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101656 $b ABA008
999    __
$a ok $b bmc $g 1690787 $s 1140511
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 267 $c 10 $d 2851-2864 $e 20200525 $i 1432-1459 $m Journal of neurology $n J Neurol $x MED00002835
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options